IceCure Medical Sees Significant Growth Post FDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Market Expansion: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, indicating accelerated commercial adoption and rising physician demand in the U.S. market.
- Clinical Acceptance Growth: The American Society of Breast Surgeons (ASBrS) recently updated its resource guidelines to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical acceptance of minimally invasive breast cancer therapies.
- Increased Patient Awareness: Patient awareness of breast cancer cryoablation continues to grow as ProSense® receives extensive media coverage, with approximately 190 CBS and CW-affiliated stations highlighting cryoablation as a minimally invasive alternative to surgery, further driving demand.
- Lead Generation Surge: At two major breast health conferences this year, IceCure generated significantly more sales leads for ProSense® systems compared to previous events, reflecting a substantial increase in interest from physicians and healthcare providers, indicating potential for future commercial opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.130
Low
3.00
Averages
3.00
High
3.00
Current: 2.130
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Medical Sees Surge in ProSense® System Demand Following FDA Approval
- Surge in Demand: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, reflecting rapid growth in physician demand and an expanding market footprint.
- Enhanced Clinical Acceptance: The American Society of Breast Surgeons updated its resource guide to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical adoption of minimally invasive therapies and further driving ProSense® market penetration.
- Increased Patient Awareness: With rising media exposure of ProSense® across the nation, patient awareness of breast cancer cryoablation continues to grow, particularly due to television coverage in cities like Boston, Philadelphia, and Chicago, which helps educate both patients and physicians about available treatment options.
- Increased Sales Leads: IceCure generated significantly more sales leads for ProSense® systems at two major breast health conferences this year compared to 2025, indicating a substantial increase in interest from physicians and healthcare providers, suggesting a promising commercial opportunity ahead.
See More
IceCure Medical Sees Significant Growth Post FDA Approval
- Market Expansion: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, indicating accelerated commercial adoption and rising physician demand in the U.S. market.
- Clinical Acceptance Growth: The American Society of Breast Surgeons (ASBrS) recently updated its resource guidelines to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical acceptance of minimally invasive breast cancer therapies.
- Increased Patient Awareness: Patient awareness of breast cancer cryoablation continues to grow as ProSense® receives extensive media coverage, with approximately 190 CBS and CW-affiliated stations highlighting cryoablation as a minimally invasive alternative to surgery, further driving demand.
- Lead Generation Surge: At two major breast health conferences this year, IceCure generated significantly more sales leads for ProSense® systems compared to previous events, reflecting a substantial increase in interest from physicians and healthcare providers, indicating potential for future commercial opportunities.
See More
IceCure Medical Announces 1-for-30 Reverse Stock Split
- Reverse Stock Split: IceCure Medical announced a 1-for-30 reverse stock split effective June 4, 2026, aimed at raising its share price above Nasdaq's minimum bid requirement of $1, thereby helping the company maintain its Nasdaq listing.
- Share Count Reduction: Following the reverse split, the outstanding share count will decrease from 84.2 million to approximately 2.8 million shares, while shareholders' ownership stakes will largely remain unchanged, impacting stock options, warrants, and equity awards.
- Compliance Deadline: The company has until November 9, 2026, to regain compliance, with the reverse split being a response to the current stock price of $0.16, which is down 19%, indicating the market pressures the company is facing.
- Market Reaction: IceCure Medical's stock is currently trading at $0.16, and the decision for a reverse split may affect investor confidence, although the company hopes to improve its stock performance and attract more investment through this measure.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq's $1.00 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to regulatory compliance and proactive management of its capital markets strategy.
- Impact on Shares: The reverse split will reduce the number of issued ordinary shares from 84,201,034 to approximately 2,806,701, ensuring that all shareholders' ownership percentages remain unchanged, although minor adjustments will be made for fractional shares to maintain fairness.
- Market Reaction Anticipation: The reverse split is set to take effect on June 4, 2026, with shares trading at the adjusted price on Nasdaq, aiming to boost investor confidence and attract further investment by enhancing the stock price.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's $1 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to compliance and proactive capital market strategies.
- Impact on Shares: Following the reverse split, the number of issued ordinary shares will decrease from 84,201,034 to approximately 2,806,701, ensuring that shareholders' percentage ownership remains unchanged, although minor adjustments will be made for fractional shares.
- Market Confidence Strategy: By implementing this reverse split, IceCure aims to enhance its stock price before the compliance deadline of November 9, 2026, thereby boosting investor confidence and supporting its broader capital market strategy.
See More
Breakthrough in Tumor Treatment with Cryoablation Technology
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
See More
IceCure Medical Sees Surge in ProSense® System Demand Following FDA Approval
- Surge in Demand: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, reflecting rapid growth in physician demand and an expanding market footprint.
- Enhanced Clinical Acceptance: The American Society of Breast Surgeons updated its resource guide to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical adoption of minimally invasive therapies and further driving ProSense® market penetration.
- Increased Patient Awareness: With rising media exposure of ProSense® across the nation, patient awareness of breast cancer cryoablation continues to grow, particularly due to television coverage in cities like Boston, Philadelphia, and Chicago, which helps educate both patients and physicians about available treatment options.
- Increased Sales Leads: IceCure generated significantly more sales leads for ProSense® systems at two major breast health conferences this year compared to 2025, indicating a substantial increase in interest from physicians and healthcare providers, suggesting a promising commercial opportunity ahead.
See More
IceCure Medical Sees Significant Growth Post FDA Approval
- Market Expansion: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, indicating accelerated commercial adoption and rising physician demand in the U.S. market.
- Clinical Acceptance Growth: The American Society of Breast Surgeons (ASBrS) recently updated its resource guidelines to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical acceptance of minimally invasive breast cancer therapies.
- Increased Patient Awareness: Patient awareness of breast cancer cryoablation continues to grow as ProSense® receives extensive media coverage, with approximately 190 CBS and CW-affiliated stations highlighting cryoablation as a minimally invasive alternative to surgery, further driving demand.
- Lead Generation Surge: At two major breast health conferences this year, IceCure generated significantly more sales leads for ProSense® systems compared to previous events, reflecting a substantial increase in interest from physicians and healthcare providers, indicating potential for future commercial opportunities.
See More
IceCure Medical Announces 1-for-30 Reverse Stock Split
- Reverse Stock Split: IceCure Medical announced a 1-for-30 reverse stock split effective June 4, 2026, aimed at raising its share price above Nasdaq's minimum bid requirement of $1, thereby helping the company maintain its Nasdaq listing.
- Share Count Reduction: Following the reverse split, the outstanding share count will decrease from 84.2 million to approximately 2.8 million shares, while shareholders' ownership stakes will largely remain unchanged, impacting stock options, warrants, and equity awards.
- Compliance Deadline: The company has until November 9, 2026, to regain compliance, with the reverse split being a response to the current stock price of $0.16, which is down 19%, indicating the market pressures the company is facing.
- Market Reaction: IceCure Medical's stock is currently trading at $0.16, and the decision for a reverse split may affect investor confidence, although the company hopes to improve its stock performance and attract more investment through this measure.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to comply with Nasdaq's $1.00 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to regulatory compliance and proactive management of its capital markets strategy.
- Impact on Shares: The reverse split will reduce the number of issued ordinary shares from 84,201,034 to approximately 2,806,701, ensuring that all shareholders' ownership percentages remain unchanged, although minor adjustments will be made for fractional shares to maintain fairness.
- Market Reaction Anticipation: The reverse split is set to take effect on June 4, 2026, with shares trading at the adjusted price on Nasdaq, aiming to boost investor confidence and attract further investment by enhancing the stock price.
See More
IceCure Medical Implements Reverse Split to Regain Nasdaq Compliance
- Reverse Split Announcement: IceCure Medical has announced a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's $1 minimum bid requirement, thereby maintaining its listing on the Nasdaq Capital Market.
- Shareholder Approval: The reverse split plan was approved by shareholders at a special meeting on May 11, 2026, indicating the company's commitment to compliance and proactive capital market strategies.
- Impact on Shares: Following the reverse split, the number of issued ordinary shares will decrease from 84,201,034 to approximately 2,806,701, ensuring that shareholders' percentage ownership remains unchanged, although minor adjustments will be made for fractional shares.
- Market Confidence Strategy: By implementing this reverse split, IceCure aims to enhance its stock price before the compliance deadline of November 9, 2026, thereby boosting investor confidence and supporting its broader capital market strategy.
See More
Breakthrough in Tumor Treatment with Cryoablation Technology
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
See More
